{'52WeekChange': 1.9155672,
 'SandP52WeekChange': 0.0644362,
 'address1': '200 Broadway',
 'address2': '3rd Floor',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 78.97,
 'askSize': 1100,
 'averageDailyVolume10Day': 340062,
 'averageVolume': 683026,
 'averageVolume10days': 340062,
 'beta': 3.141122,
 'beta3Year': None,
 'bid': 76.76,
 'bidSize': 800,
 'bookValue': 4.212,
 'category': None,
 'circulatingSupply': None,
 'city': 'New York',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 79.68,
 'dayLow': 76.805,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -34.083,
 'enterpriseToRevenue': None,
 'enterpriseValue': 2690623488,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '212 320 0245',
 'fiftyDayAverage': 79.56743,
 'fiftyTwoWeekHigh': 109.94,
 'fiftyTwoWeekLow': 13.64,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 27199283,
 'forwardEps': -2.91,
 'forwardPE': -26.580755,
 'fromCurrency': None,
 'fullTimeEmployees': 45,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.22226,
 'heldPercentInstitutions': 0.61098,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/axsome.com',
 'longBusinessSummary': 'Axsome Therapeutics, Inc., a clinical stage '
                        'biopharmaceutical company, engages in developing '
                        'novel therapies for central nervous system (CNS) '
                        'disorders in the United States. Its product pipeline '
                        'includes AXS-05, which is in the phase III clinical '
                        'trial for the treatment resistant depression and '
                        'depressive disorders; and phase II/III clinical '
                        "trials in agitation associated with Alzheimer's "
                        'disease, as well as completed phase II clinical trial '
                        'for the treatment of smoking cessation. The company '
                        'is also developing AXS-07, which is in phase III '
                        'clinical trial for the treatment of migraine; AXS-09 '
                        'that has completed phase II clinical trial for the '
                        'treatment of various CNS disorders; AXS-12, which has '
                        'completed phase II clinical trial for the treatment '
                        'of in narcolepsy; and AXS-14, an investigational '
                        'medicine that is in phase III for the treatment of '
                        'fibromyalgia. Axsome Therapeutics, Inc. has a '
                        'research collaboration agreement with Duke University '
                        'for evaluating AXS-05 in smoking cessation. The '
                        'company was founded in 2012 and is based in New York, '
                        'New York.',
 'longName': 'Axsome Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 2867820800,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_241907563',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -90188960,
 'nextFiscalYearEnd': 1640908800,
 'open': 79.26,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '212 332 3241',
 'previousClose': 79.9,
 'priceHint': 2,
 'priceToBook': 18.364197,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 79.68,
 'regularMarketDayLow': 76.805,
 'regularMarketOpen': 79.26,
 'regularMarketPreviousClose': 79.9,
 'regularMarketPrice': 79.26,
 'regularMarketVolume': 346956,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 37075900,
 'sharesPercentSharesOut': 0.103999995,
 'sharesShort': 3855679,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 3397422,
 'shortName': 'Axsome Therapeutics, Inc.',
 'shortPercentOfFloat': 0.1337,
 'shortRatio': 5.97,
 'startDate': None,
 'state': 'NY',
 'strikePrice': None,
 'symbol': 'AXSM',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.575,
 'twoHundredDayAverage': 79.10906,
 'volume': 346956,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.axsome.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '10038'}